Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Diabetes

Insulin plus metformin for T2DM—are there benefits?

Nature Reviews Endocrinology volume 8, pages 449–450 (2012)Cite this article

Subjects

When insulin therapy is introduced in advanced stages of type 2 diabetes mellitus many patients are already being treated with metformin and continue to receive this oral antihyperglycaemic agent. In a systematic review and meta-analysis, Hemmingsen et al. have evaluated the evidence for the benefits of this combination therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Suggested mechanism for the actions of metformin and its interactions with the insulin signalling pathway.

References

  1. Inzucchi, S. E. et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55, 1577–1596 (2012).

    Article  CAS  Google Scholar 

  2. Hemmingsen, B. et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ http://dx.doi.org/10.1136/bmj.e1771.

  3. Bailey, C. J. et al. in Metformin, the Gold Standard. A scientific handbook. (ed. Bailey, C. J. et al.) 1–288 (Wiley, Chichester, 2007)

    Google Scholar 

  4. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998).

  5. Johnson, J. A., Simpson, S. H., Toth, E. L. & Majumdar S. R. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabetic Med. 22, 497–502 (2005).

    Article  CAS  Google Scholar 

  6. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Neil, H. A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008).

    Article  CAS  Google Scholar 

  7. Skyler, J. S. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32, 187–192 (2009).

    Article  Google Scholar 

  8. Kooy, A. et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern. Med. 169, 616–625 (2009).

    Article  CAS  Google Scholar 

  9. Zhang, B. B., Zhou, G. & Li, C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 9, 407–416 (2009).

    Article  Google Scholar 

  10. Bailey, C. J. Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc. Drugs Ther. 22, 215–224 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Life and Health Sciences, Aston University, Gosta Green, Birmingham, B4 7ET, UK

    Clifford J. Bailey

Authors
  1. Clifford J. Bailey
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares associations with the following companies: Astra Zeneca, Bristol-Myers Squibb, Lilly, MSD and Novo Nordisk (consultancy/speakers bureau); and Boehringer Ingelheim, GlaxoSmithKline, Sanofi and Takeda (consultancy).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bailey, C. Insulin plus metformin for T2DM—are there benefits?. Nat Rev Endocrinol 8, 449–450 (2012). https://doi.org/10.1038/nrendo.2012.106

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2012.106

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing